SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-041223
Filing Date
2023-11-14
Accepted
2023-11-14 16:51:02
Documents
15
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45837
2 ex99-1.htm EX-99.1 65786
3 ex99-1_001.jpg GRAPHIC 2996
  Complete submission text file 0001493152-23-041223.txt   344176

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cldi-20231114.xsd EX-101.SCH 3765
5 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cldi-20231114_def.xml EX-101.DEF 26611
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cldi-20231114_lab.xml EX-101.LAB 36667
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cldi-20231114_pre.xml EX-101.PRE 25235
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5382
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 231407509
SIC: 2836 Biological Products, (No Diagnostic Substances)